


CURRICULUM VITAE FOR ACADEMIC PROMOTION

The Johns Hopkins University School of Medicine



Emmanuel S. Antonarakis

5/2/2019

DEMOGRAPHIC INFORMATION

Current Appointments

2015 - Present Associate Professor of Oncology and Urology
Director of Prostate Cancer Medical Oncology Research
Co-Director of Prostate Cancer Multi-Disciplinary Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, JHU School of Medicine
James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine

Personal Data:

Prostate Cancer Program
CRB1 – Room 1M45
1650 Orleans Street
Baltimore, MD 21231
Tel 443-287-0553; Fax 410-614-8397
eamtona1@jhmi.edu

EDUCATION AND TRAINING (in chronological order)

Undergraduate

2000 B.S., Medical Genetics, University of Wales College of Medicine, Cardiff, U.K.

Doctoral/Graduate

2003 MB.BCh. (M.D. equivalent), Medicine, University of Wales College of Medicine, Cardiff, U.K.

Postdoctoral

2003 - 2004 Intern, Medicine & Surgery, University Hospital of Wales, Cardiff, U.K.
2004 - 2007 Resident, Internal Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD
2007 - 2010 Fellow, Medical Oncology, Johns Hopkins Hospital, Baltimore, MD

Professional Experience

2003 - 2004 Intern in Medicine and Surgery, University Hospital of Wales, Cardiff, U.K.
2004 - 2007 Resident in Internal Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD
2007 - 2010 Clinical Fellow in Medical Oncology, Johns Hopkins Hospital, Baltimore, MD
2010 - 2015 Assistant Professor of Oncology and Urology, Sidney Kimmel Cancer Center, Baltimore, MD
2015 - Present Associate Professor of Oncology and Urology, Sidney Kimmel Cancer Center, Baltimore, MD
2016 - Present Co-Director of Prostate Cancer Multi-Disciplinary Clinic, Sidney Kimmel Cancer Center
2016 - Present Director of Prostate Cancer Medical Oncology Research, Sidney Kimmel Cancer Center

RESEARCH ACTIVITIES

Dr. Antonarakis has primarily focused his research efforts on the design and conduct of translational clinical trials bringing novel therapies to men with recurrent and advanced prostate cancer, as well as the identification and clinical validation of predictive tissue-based and blood-based genomic biomarkers for patients with advanced prostate cancer. His five most significant areas of scientific contribution to date include: **(1)** Understanding the natural history of biochemically-recurrent prostate cancer (BRPC) and the design of clinical trials in this population; **(2)** Developing novel therapies for men with metastatic castration-resistant prostate cancer (mCRPC) and understanding optimal treatment sequencing in these patients; **(3)** Identification and clinical validation of biomarkers including the AR splice variant 7 (AR-V7) as a treatment-selection marker in men with metastatic castration-resistant prostate cancer (mCRPC); **(4)** Understanding the clinical significance and therapeutic implications of germline and/or somatic DNA repair gene mutations in the context of recurrent and advanced prostate cancer; and **(5)** Developing immunotherapy approaches for the treatment of localized and advanced prostate cancers.